Skip to main content
. Author manuscript; available in PMC: 2023 Jun 15.
Published in final edited form as: Clin Cancer Res. 2022 Dec 15;28(24):5405–5418. doi: 10.1158/1078-0432.CCR-22-0963

Fig. 1. Tumor growth inhibition by siHIF2 in ccRCC TGs.

Fig. 1.

A. Representative T2-weighted MRI images at baseline and after administration of A1HIF2 with corresponding tumor volume quantitation. B. Tumor volume by MRI (n=3 per arm) at baseline and at the end of treatment. C. Actual tumor volume measurements at the end of treatment. D. Tumor weight at the end of treatment. *, p < 0.05; **, p<0.01; ****, p < 0.0001. Error bars represent standard deviation.